MDxHealth Announces Launch of Offering of Ordinary Shares
MDxHealth SA (NASDAQ: MDXH) has announced the launch of a proposed offering of $40.0 million of ordinary shares in a registered public offering. The company plans to grant underwriters a 30-day option to purchase up to 15% additional ordinary shares. TD Cowen and William Blair are acting as joint book-running managers for the offering.
The offering is subject to market conditions, with no assurance of completion or final terms. A preliminary prospectus supplement has been filed with the SEC. The shares are being offered pursuant to a previously filed and effective registration statement. This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities.
MDxHealth SA (NASDAQ: MDXH) ha annunciato il lancio di un'offerta proposta di 40,0 milioni di dollari di azioni ordinarie in un'offerta pubblica registrata. L'azienda prevede di concedere ai sottoscrittori un'opzione di 30 giorni per acquistare fino al 15% di azioni ordinarie aggiuntive. TD Cowen e William Blair stanno agendo come gestori congiunti per l'offerta.
L'offerta è soggetta alle condizioni di mercato, senza alcuna garanzia di completamento o di termini finali. È stato presentato un supplemento preliminare al prospetto alla SEC. Le azioni sono offerte ai sensi di una dichiarazione di registrazione già presentata ed efficace. Questo annuncio non costituisce un'offerta di vendita né una sollecitazione di un'offerta di acquisto di titoli.
MDxHealth SA (NASDAQ: MDXH) ha anunciado el lanzamiento de una oferta propuesta de 40,0 millones de dólares de acciones ordinarias en una oferta pública registrada. La empresa planea otorgar a los suscriptores una opción de 30 días para comprar hasta un 15% adicional de acciones ordinarias. TD Cowen y William Blair están actuando como gerentes conjuntos de la oferta.
La oferta está sujeta a las condiciones del mercado, sin garantía de finalización o de términos finales. Se ha presentado un suplemento preliminar de prospecto ante la SEC. Las acciones se ofrecen en virtud de una declaración de registro presentada y efectiva anteriormente. Este anuncio no constituye una oferta para vender ni una solicitud de una oferta para comprar valores.
MDxHealth SA (NASDAQ: MDXH)는 등록된 공모에서 4천만 달러의 보통주를 제안하는 출범을 발표했습니다. 이 회사는 인수인에게 15%의 추가 보통주를 구매할 수 있는 30일 옵션을 제공할 계획입니다. TD Cowen과 William Blair는 이번 공모의 공동 주선 관리자 역할을 하고 있습니다.
이번 공모는 시장 상황에 따라 다르며, 완료 또는 최종 조건에 대한 보장이 없습니다. SEC에 초기 투자설명서 보충이 제출되었습니다. 주식은 이전에 제출된 유효한 등록 진술서에 따라 제공됩니다. 이 발표는 증권을 판매하기 위한 제안이나 구매 제안의 소집으로 간주되지 않습니다.
MDxHealth SA (NASDAQ: MDXH) a annoncé le lancement d'une offre proposée de 40 millions de dollars d'actions ordinaires dans le cadre d'une offre publique enregistrée. La société prévoit de donner aux souscripteurs une option de 30 jours pour acheter jusqu'à 15% d'actions ordinaires supplémentaires. TD Cowen et William Blair agissent en tant que co-gestionnaires de livre pour l'offre.
L'offre est soumise aux conditions du marché, sans garantie de réalisation ou de conditions finales. Un supplément de prospectus préliminaire a été déposé auprès de la SEC. Les actions sont offertes conformément à une déclaration d'enregistrement précédemment déposée et effective. Cette annonce ne constitue pas une offre de vente ni une sollicitation d'offre d'achat de titres.
MDxHealth SA (NASDAQ: MDXH) hat den Start eines vorgeschlagenen Angebots von 40 Millionen Dollar für Stammaktien in einem registrierten öffentlichen Angebot bekannt gegeben. Das Unternehmen plant, den Underwritern eine 30-tägige Option zu gewähren, um bis zu 15% zusätzliche Stammaktien zu kaufen. TD Cowen und William Blair fungieren als gemeinsame Buchmanager für das Angebot.
Das Angebot unterliegt den Marktbedingungen, und es besteht keine Garantie für den Abschluss oder die endgültigen Bedingungen. Ein vorläufiges Prospektnachtragsformular wurde bei der SEC eingereicht. Die Aktien werden gemäß einer zuvor eingereichten und wirksamen Registrierungserklärung angeboten. Diese Bekanntmachung stellt kein Angebot zum Verkauf dar und ist auch keine Aufforderung zur Abgabe eines Kaufangebots für Wertpapiere.
- Potential to raise $40.0 million in capital through the offering
- 30-day option for underwriters to purchase up to 15% additional shares, potentially increasing capital raised
- Involvement of reputable joint book-running managers (TD Cowen and William Blair)
- Potential dilution of existing shareholders' ownership
- Uncertainty regarding the final terms and completion of the offering
- Market conditions may affect the success and pricing of the offering
Insights
MDxHealth's proposed
The offering's success and pricing will be important indicators of investor confidence in MDxHealth's growth prospects and cash needs. The inclusion of a 30-day option for underwriters to purchase up to
Investors should closely monitor the final terms, including share price and number of shares issued, to assess the offering's impact on ownership structure and earnings per share. The use of proceeds will be critical in evaluating how effectively the company can deploy this capital to drive growth and potentially reach profitability in its precision diagnostics business.
This offering comes at a pivotal time for MDxHealth as it seeks to capitalize on the growing precision diagnostics market. The involvement of reputable underwriters like TD Cowen and William Blair lends credibility to the offering and may attract institutional investors.
However, the success of this capital raise will largely depend on market conditions and investor appetite for biotech stocks, which have faced challenges recently. The offering's impact on MDxHealth's stock price in the short term could be negative due to dilution concerns, but long-term prospects may improve if the funds are effectively utilized to expand market share and develop new diagnostic products.
Investors should consider MDxHealth's competitive position, revenue growth trajectory and pipeline of diagnostic tests when evaluating this offering's potential to enhance the company's market position. The outcome of this offering could significantly influence MDxHealth's ability to compete effectively in the rapidly evolving precision medicine landscape.
MDxHealth Announces Launch of Offering of Ordinary Shares
IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of
The Ordinary Shares described above are being offered by mdxhealth pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to the Offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities, if at all, will be made in accordance with the registration requirements of the United States Securities Act of 1933.
Copies of the preliminary prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by email at TD.ECM_Prospectus@tdsecurities.com or by telephone at (855) 495-9846 and William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.
For more information:
mdxhealth
info@mdxhealth.com
LifeSci Advisors (IR & PR)
US: +1 949 271 9223
ir@mdxhealth.com
IMPORTANT INFORMATION
This press release contains forward-looking statements regarding the proposed offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed in the section “Risk Factors” included in the preliminary prospectus supplement for the offering and in greater detail in our filings with the SEC. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of mdxhealth in any jurisdiction. No securities of mdxhealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (the “Prospectus Regulation”), will not be eligible to participate in the Offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, persons falling within the meaning of Article 2(e) of the Prospectus Regulation, and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated.
Attachment
FAQ
What is the size of MDxHealth's proposed offering of ordinary shares?
Who are the joint book-running managers for MDxHealth's share offering?
What option is MDxHealth granting to the underwriters in this offering?
Has MDxHealth filed a prospectus for this offering with the SEC?
